2160.T) announced that its subsidiary, Gyre Therapeutics, submitted a New Drug Application (NDA) to">
PULSE NEWS WIRE
Clear, Actionable Intelligence
<2 min
Avg Latency
24/5
Coverage

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from GNI Group Ltd. was processed by Pulse News Wire on March 24, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

GNI Group: Files NDA for Liver Fibrosis Drug F351 in China

TOKYO, Mar 24 (Pulse News Wire) – GNI Group Ltd. (2160.T) announced that its subsidiary, Gyre Therapeutics, submitted a New Drug Application (NDA) to China's National Medical Products Administration (

View all 2160.T disclosures →

Share this disclosure: Share on X Share on LinkedIn